Stereotactic Ablative Radiotherapy (Sabr) as a New Precision Treatment Option in Kidney Cancer

Stereotactic ablative body radiotherapy for primary kidney cancer (TROG 15.03 FASTRACK II): a non-randomised phase 2 trial

Shankar Siva, Mathias Bressel, Mark Sidhom, Swetha Sridharan, Ben GL Vanneste, Ryan Davey, Rebecca Montgomery, Jeremy Ruben, Farshad Foroudi, Braden Higgs, Charles Lin, Avi Raman, Nicholas Hardcastle, Michael S Hofman, Richard De Abreu Lourenco, Mark Shaw, Pascal Mancuso, Daniel Moon, Lih-Ming Wong, Nathan Lawrentschuk

2024-03-01

Background: Stereotactic ablative body radiotherapy (SABR) is a novel non-invasive alternative for patients with primary renal cel..

Prospective knowledge-based planning for personalised plan QA in a multi-centre kidney SABR trial

N Hardcastle, O Cook, X Ray, A Moore, K Moore, D Pryor, A Rossi, F Foroudi, T Kron, S Siva

2021-08-01

TROG 15.03 phase II clinical trial of Focal Ablative STereotactic Radiosurgery for Cancers of the Kidney - FASTRACK II

S Siva, B Chesson, M Bressel, D Pryor, B Higgs, HM Reynolds, N Hardcastle, R Montgomery, B Vanneste, V Khoo, J Ruben, E Lau, MS Hofman, R De Abreu Lourenco, S Sridharan, NR Brook, J Martin, N Lawrentschuk, T Kron, F Foroudi

2018-10-23

Background: Stereotactic ablative body radiotherapy (SABR) is a non-invasive alternative to surgery to control primary renal cell ..